首页|期刊导航|医药导报|信迪利单抗治疗实体瘤致免疫相关性甲状腺功能异常的影响因素及预测模型构建

信迪利单抗治疗实体瘤致免疫相关性甲状腺功能异常的影响因素及预测模型构建

崔艳军黄琳张晓红马天刘一赵立波杜心怡焦玲柴爱军樊榕榕刘彦国

医药导报2025，Vol.44Issue(10)：1556-1561,6.

医药导报2025，Vol.44Issue(10)：1556-1561,6.DOI:10.3870/j.issn.1004-0781.2025.10.005

信迪利单抗治疗实体瘤致免疫相关性甲状腺功能异常的影响因素及预测模型构建

Influencing Factor Analysis and Prediction Model Construction of Immune-Related Thyroid Dysfunction Caused by Sintilimab Treatment in Solid Tumors

崔艳军 ¹黄琳 ²张晓红 ²马天 ¹刘一 ³赵立波 ⁴杜心怡 ⁵焦玲 ¹柴爱军 ¹樊榕榕 ⁶刘彦国⁶

作者信息

1. 石家庄市人民医院/北京大学人民医院石家庄医院药学部,石家庄 050000
2. 北京大学人民医院药学部,北京 100044
3. 石家庄市人民医院/北京大学人民医院石家庄医院药学部,石家庄 050000||北京大学人民医院药学部,北京 100044
4. 北京大学第三医院药剂科,北京 100191
5. 石家庄市人民医院/北京大学人民医院石家庄医院内分泌科,石家庄 050000
6. 北京大学人民医院胸外科,北京 100044
折叠

摘要

Abstract

Objective To explore the influencing factors of immune-associated thyroid dysfunction caused by sintilimab treatment in solid tumors and construct a prediction model.Methods Medical records of patients diagnosed with solid tumors and treated with sintilimab at Peking University People's Hospital(Xizhimen Campus,Tongzhou Campus,Shijiazhuang Campus)from January 2023 to September 2024 were collected to explore the influencing factors that caused immune-related thyroid dysfunction using univariate and multifactorial binary logistic regression analyses and to establish a prediction model.The predictive effect of the model was assessed using the receiver operating characteristic(ROC)curve.Results A total of 120 patients were included,and 33 presented with immune-related thyroid dysfunction.Multifactorial logistic regression analysis revealed that thyroid-stimulating hormone(TSH)[OR=2.470,95%CI=(1.279,4.771)]and treatment cycles[OR=1.298,95%CI=(1.117,1.509)]were independent risk factors for the occurrence of immune-associated thyroid dysfunction,and the difference was statistically significant(P＜0.05).The area under the ROC curve was(0.897±0.043)[95%CI=(0.813,0.981)],the Yoden index was 0.703,and the model prediction accuracy was 86.5%.Conclusion The risk of immune-related thyroid dysfunction caused by sintilimab is high,and TSH and treatment cycle are the influencing factors,and the constructed model has certain predictive value and is of reference significance.

关键词

信迪利单抗/甲状腺功能异常/程序性死亡受体1 抑制剂/免疫相关不良事件

Key words

Sintilimab/Thyroid dysfunction/Programmed cell death-1 inhibitors/Immune-related adverse events

分类

医药卫生

引用本文复制引用

崔艳军,黄琳,张晓红,马天,刘一,赵立波,杜心怡,焦玲,柴爱军,樊榕榕,刘彦国..信迪利单抗治疗实体瘤致免疫相关性甲状腺功能异常的影响因素及预测模型构建[J].医药导报,2025,44(10):1556-1561,6.

基金项目

白求恩求索-药学科研能力建设项目(B-19-H-20200622). （B-19-H-20200622）

医药导报

OA北大核心

ISSN：1004-0781

访问量0

下载量0

段落导航